Newswise — BOSTON – (May 6, 2014) – Three researchers from Joslin Diabetes Center will be presented with awards at the American Diabetes Association’s (ADA) 74th Scientific Sessions. They are Edward Horton, M.D., Andrzej Krolewski, M.D., Ph.D. and Katie Weinger, Ed.D., R.N.

“We are thrilled and proud that three of our outstanding researchers have been recognized for their scientific excellence and their distinguished careers,” said John L. Brooks III, President and CEO of Joslin Diabetes Center. “Having three prestigious ADA awards bestowed on our esteemed faculty is a great recognition of each of them, and it is a great endorsement of the global research and clinical leadership that exists at Joslin.” Edward Horton, M.D., Senior Investigator at Joslin and Professor of Medicine at Harvard Medical School, will receive the 2014 Albert Renold Award. This award was named for Albert Renold, M.D., who served as the Director of The Baker Clinic Research Laboratory, which later became the Elliott P. Joslin Research Laboratory, at Joslin from 1959 until 1962. The Albert Renold award is one of the ADA’s highest scientific awards that is given annually to an individual who has made a significant impact as a mentor to diabetes researchers or to a community of diabetes investigators.

The 2014 Kelly West Award in Epidemiology will be presented to Andrzej Krolewski, M.D., Ph.D., Head of the Section on Genetics and Epidemiology at Joslin and Professor of Medicine at Harvard Medical School. This award recognizes Dr. Krolewski’s triumphs in diabetes epidemiology and is given annually to an individual who has made significant contributions to the field. It was Dr. Kelly West – the “father of diabetes epidemiology" – who arranged for Dr. Krolewski to come to Joslin in 1980 to develop epidemiology research. Along with his award, Dr. Krolewski will deliver the lecture, “Time to Retire ‘Microalbuminuria’: Early, Progressive Renal Decline is the New Paradigm.”

The third recipient is Katie Weinger, Ed.D., R.N., Investigator in the Section of Clinical, Behavioral and Outcomes Research at Joslin and an Associate Professor of Psychiatry at Harvard Medical School, who will receive the 2014 Outstanding Diabetes Educator Award, which is bestowed to a health professional who makes exceptional educational efforts in the field of diabetes and demonstrates significant contributions to the understanding of diabetes education. Dr. Weinger will also present the lecture, “Six Impossible Things Before Breakfast: Examining Diabetes Self-care” at the Scientific Sessions.

“These are major awards and most institutions are happy to just receive one award, so Joslin is thrilled to receive three awards,” said George King, M.D., Chief Scientific Officer and Senior Vice President at Joslin.

The annual Scientific Sessions, hosted by the ADA, is the world’s largest diabetes meeting and brings together nearly 18,000 participants, with more than 14,000 clinicians and researchers from 118 countries. The five day meeting showcases timely and significant advances in basic science and the prevention, diagnosis and treatment of diabetes.

About Joslin Diabetes Center

Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes.

Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care.

Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit

About Joslin Research

Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30‐plus faculty‐level investigators, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications. Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.

Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit